NCT Number: NCT02234882
Study on Pharmacokinetics
The purpose of this study is to assess the effect of the coadministration of multiple doses of BMS-663068 on the systemic exposure of rosuvastatin.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Signed Informed Consent Form
- Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocol-required procedures.
- Target Population
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, vital sign measurements, 12-lead ECG measurements, and clinical laboratory test results.
- Age and Reproductive Status
- Men and women of non-childbearing potential, ages 18 to 50 years, inclusive. Women must have documented proof that they are not of childbearing potential. Women must not be breastfeeding.
- Males who are sexually active with women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s).
Exclusion criteria
- Women who are of childbearing potential or breastfeeding
- Any significant acute or chronic medical illness
- History of rhabdomyolysis or biliary disorders, including Gilbert's disease or Dubin-Johnson disease
- Smokers (those who currently smoke, as well as those who have stopped smoking less than 6 months prior to the start of study drug administration)
- Alcohol intake exceeding 2 standard drinks per days; however, no alcohol is allowed 1 week prior to the start of study drug administration and for the duration of the study
- Any other sound medical, psychiatric, and/or social reason as determined by the investigator
Treatment and study plan
BMS-663068
DrugPrimary outcomes
-
Maximum observed plasma concentration (Cmax) of rosuvastatin
Time frame: Days 1 through 13
-
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[INF]) of rosuvastatin
Time frame: Days 1 through 13
Secondary outcomes
-
Trough blood samples of BMS-626529 concentration
Time frame: Days 7 through 13
-
Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.
Time frame: 40 days
Sponsors and collaborators
Lead sponsor
ViiV Healthcare
Industry
Collaborators
- GlaxoSmithKline
Registry information
Official study title
Effect of BMS-663068 on the Pharmacokinetics of Rosuvastatin
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Sep 9, 2014
- Registry last updated
- Apr 17, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study Among People Living With HIV and Their Health Professionals of Associated Factors of Resilience to Self-stigma
NCT05149001
Behavior, Blood-Borne Infections
Aix-en-Provence, France
View Trial DetailsSkills to Empower Affirmative Men
NCT05732675
Behavior, Bisexuality
Ho Chi Minh City, Vietnam
View Trial DetailsImplementation and Assessment of a Medication Therapy Management Program in HIV Patients at High Risk of Adverse Drug Events at Khartoum, Sudan
NCT07750834
Acquired Immunodeficiency Syndrome, Behavior
Khartoum, Omdurman, Sudan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
NCT06012136
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Las Vegas, Nevada, United States
View Trial Details